Publications included in qualitative synthesis (n=70) Humanistic: n=20 Economic burden: n=14 Economic models: n=14
Epidemiology: n=22
Records after duplicates removed (n=3,573)
Additional records identified through grey literature c (n=5) Abbreviations: PRO, patient-reported outcome; SCT, stem cell transplantation a Our systematic review covered four burden of illness topics: epidemiology, humanistic burden, economic burden, and economic models. Only the results of the humanistic burden review are presented in this poster. b The search strategy for humanistic burden data was conducted as part of a wider search that included a search for epidemiological data; exclusion criteria related to country of study were used for studies that only reported epidemiological data. c These were abstracts presented in conference proceedings that were searched. None of the included conference abstracts from the American Society of Hematology or the European Hematology Association conferences provided data of relevance to the review of humanistic burden. 
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RESULTS (CONT'D)
HRQoL in patients with MM deteriorates with disease duration, symptom severity, disease progression, or development of complications, and is worse in patients with progressive disease or on currently available active treatments than in those in remission. This evidence suggests substantial unmet needs in MM patients.
The study aimed to examine the humanistic burden associated with MM in general, as well as with relapsed MM (RMM) or relapsed and refractory MM (RRMM)-a topic not previously explored in a systematic literature review (SLR).
Study Characteristics
Overall, 20 publications reporting on a total of 18 observational studies were included in the review. A summary of the key characteristics of these studies is presented in Table 2 . Figure 1 outlines the selection of studies from the initial search hits to the final number of studies synthesised in our review (including the numbers of results retrieved from both the original RMM or RRMM search and the later search in MM in general), using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement guidelines.
Search Results
As indicated, the systematic review also involved identification of epidemiology, economic burden, and economic models, but only the results of the humanistic burden review are reported here.
Adverse Events Related to Treatments for MM Cause Significant Worsening in HRQoL and Other PROs
Patients on active treatment had worse side effects than those in a first treatment-free interval (p<0.001), as measured by the EORTC-QLQ-MY20 Side Effects score (although the specific effects involved, or which were most bothersome, was not reported in the study). 15 
HRQoL and Other PROs Worsen in Patients with MM as the Disease Progresses
Between baseline and 1 year, patients experienced significant deterioration in HRQoL as measured on the EORTC-QLQ-C30 subscales for QoL (from 68 to 55, p<0.001), Fatigue (from 33 to 39, p<0.05), Nausea/Vomiting (from 6.3 to 13, p<0.05), Pain (from 33 to 43, p<0.05), and Dyspnoea (from 17 to 33, p<0.001). 8, 16 For each additional year of disease, patients with MM had a statistically significant 1-point reduction in global HRQoL, as measured by EORTC-QLQ-C30 (p<0.05).
More advanced stages of MM (as measured using the Durie and Salmon staging system) were a significant predictor of poorer fatigue-related QoL, as measured by the FACT-An (p<0.01).
14 Mean EQ-5D-derived utility decreased as disease severity increased, from asymptomatic (mean utility score: 0.923) to severely symptomatic (mean utility score: 0.501). Mean EQ-5D-derived utility was highest in those in a first treatment-free interval: 0.72 compared to 0.63 in the first-line and later-stage treatment groups and 0.67 in the second-line treatment group. 15 
Comorbidities Among Patients with MM Cause Deterioration in HRQoL and Other PROs
Concurrent hypertension or cardiovascular diseases significantly predicted poorer FACT-An scores in patients with MM.
14 With each additional comorbidity, patients experience worsening of fatigue (e.g., increase in EORTC QLQ-C30 Fatigue subscale score, from multiple linear regression: 2.55, 95% confidence interval: 0.36-4.73, p<0.05).
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Humanistic Burden Findings
Multiple Myeloma Causes Deterioration in HRQoL and Other PROs
Patients with MM had statistically significantly poorer HRQoL compared to the general population, as measured by the Short-Form 12 (SF-12), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire -Core 30 (EORTC-QLQ-C30), and EORTC-QLQ Multiple Myeloma-specific Module (EORTC-QLQ-MY20).
7-9
Limited evidence suggested that patients with MM had more impaired physical functioning (as assessed by the Physical Functioning subscore of the EORTC-QLQ-C30), and experienced a greater mean number of disease symptoms (such as pain, fatigue, nausea/emesis, dyspnoea, appetite loss, insomnia, diarrhoea, and constipation) 10 , than did those with other haematological cancers, including leukaemia and lymphoma.
11, 12
Disease Complications Associated with MM Cause Significant Worsening in HRQoL and other PROs
Patients with MM complications such as fatigue, bone pain, and anaemia had significantly poorer PROs as measured by EORTC-QLQ-C30 Global Health Status/QoL score, Functional Assessment of Cancer TherapyAnaemia (FACT-An) score, and FACT-Fatigue (FACT-F) score compared with patients without such features. 5, 8, 13, 14 MM patients who were symptomatic had poorer physical functioning than did asymptomatic patients (i.e., patients with severe, moderate, and mild symptom levels experienced a 24-, 13-, and 11-point reduction versus those with no symptoms, respectively, p<0.05), and patients with more severe and moderate symptoms had poorer global HRQoL (19 and 12 points lower than asymptomatic patients, respectively, p<0.05) as measured by the EORTC-QLQ-C30 in both cases (presence and severity of symptoms were assessed using the investigators' own scale). 5 An SLR was conducted initially to examine humanistic burden in patients with RMM or RRMM. The topic was then expanded to patients with MM in general (Tables 1a and 1b) .
Since broadening the scope of the review led to identification of a large number of publications relative to the search on RMM/RRMM, additional screening criteria were applied to the studies identified as part of the expanded search.
Multiple myeloma (MM) accounts for approximately 1% of all cancers and 13% of haematologic malignancies. [1] [2] [3] [4] It is a disabling as well as life-limiting condition.
Advances in drug treatments and stem cell transplantation (SCT) have led to both improved survival and increased costs in MM.
These factors emphasise the need for a clear understanding of humanistic outcomes in MM, particularly given that the disease remains incurable despite the advent of new treatments; progression of the disease cannot be indefinitely halted and is associated with the development of complications which further impair patients' healthrelated quality of life (HRQoL). 5 In addition, exposure to multiple lines of treatment is associated with adverse events that affect HRQoL. 6 Data identified in this review show that patients with MM who responded to initial treatment and who are in their first treatment-free interval have better HRQoL and utilities compared to those who progressed after initial treatment and are receiving second-line or later-line treatment. Asymptomatic patients and those with milder symptoms also have better utilities than patients with severe symptoms.
HRQoL deteriorates with each additional year a patient has MM; the more severe a patient's symptoms (compared with those with moderate to mild symptoms), the greater the impairment of HRQoL; and more advanced stage of MM is a predictor of fatigue-related decreased HRQoL.
Disease complications of MM, including fatigue, bone pain, and anaemia, also cause statistically significant deterioration in HRQoL in general and in symptom-specific PROs. Additionally, an increase in the number of comorbidities is associated with poorer HRQoL.
These findings demonstrate the need for effective treatments that both delay disease progression in MM and reduce the impact of disease complications and symptoms on patient burden.
Most of the studies identified were either in newly diagnosed or treatment-naïve patients with MM. Little information was available on patients with relapsed or refractory disease.
Limited data were found on the impact of specific adverse events on PROs, or on the effect of specific comorbidities on PROs.
Also, there is only limited real-world evidence on whether or how response to treatment improves HRQoL, with a particular lack of realworld evidence on how pharmacological treatment in the RMM or RRMM setting affects PROs.
